Altre lingue Regeneron Pharmaceuticals, Inc.

Azioni

REGN

US75886F1075

Biotecnologia

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 02/12/2024			Variaz. 5gg	Var. 1 gen.
762,34 ^USD	+1,62%		+1,71%	-13,20%

25/11	Nex-z di Intellia Therapeutics riceve la designazione di terapia avanzata di medicina rigenerativa da parte della FDA	MT
20/11	Laekna, biotecnologia con sede in Cina, si allea con Lilly per sviluppare un farmaco per l'obesità che preserva i muscoli	RE

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors	18:01
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors	27/11
Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors	26/11
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation	25/11
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug	20/11
Regeneron Pharmaceuticals, Inc. - Dupixent sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria	18/11
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU	15/11
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Application for Skin Disease Treatment	15/11
Jay Powell plombe un peu l'ambiance	15/11
En Direct des Marchés : ça bouge sur Nexans et Robertet, OPA possible sur Evotec, AMAT souffre	15/11
Sanofi : la FDA va examiner une nouvelle demande d'indication du Dupixent contre l'urticaire	15/11
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)	15/11
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?	15/11
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH	13/11
Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting	13/11
Regeneron Announces Investor Conference Presentations	11/11
Regeneron Announces Investor Conference Presentations	11/11
Trump makes Wall Street shine and depresses Europe	11/11
Analyst recommendations: Moderna, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals, Arista Networks...	11/11
Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment	06/11
Le Dupixent de Sanofi approuvé en Europe contre l'oesophagite à éosinophiles du jeune enfant	06/11
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis	06/11
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis	06/11
Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis	06/11
Regeneron Pharmaceuticals Insider Sold Shares Worth $844,610, According to a Recent SEC Filing	05/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Regeneron Pharmaceuticals, Inc.

Azioni

REGN

US75886F1075

Biotecnologia

Altre lingue

Filtri